PEPTIDE CORPUS

Condition

Premature LH surge

2 compounds were checked against premature lh surge, and every one of them earned a row.

Last updated

2compounds checked
2earned a graded row
2measured the condition
0mechanistic only

Compounds with a graded row

Ordered by rung, strongest first. The rung rates the study design; the chip beside it says what the study measured. Both are needed.

  1. Cetrorelix

    human RCT Direct outcome Approved for this condition

    Who was studied
    women aged 19-40 (mean 32) undergoing controlled ovarian stimulation, n=732 across five trials (two Phase 2, three Phase 3); PCOS, low or absent ovarian reserve, and stage III-IV endometriosis excluded

    FDA-approved indication is "the inhibition of premature LH surges in women undergoing controlled ovarian stimulation" — this condition is the registrational endpoint itself, not an adjunct measure. In the label's clinical trials a premature LH surge (LH >= 10 U/L with progesterone >= 1 ng/mL) occurred in 0 of 115 women on the single 3 mg dose, 1.9% of 159 on 0.25 mg daily in the comparative study, and 1.0% of 303 in the non-comparative study.

    Source DailyMed — the FDA label 1 primary source read for this row

  2. Ganirelix

    human RCT Direct outcome Approved for this condition

    Who was studied
    women undergoing controlled ovarian hyperstimulation, multicentre open-label randomised study, n=463 on ganirelix 250 mcg subcutaneously daily from day 6 of recombinant FSH, with a luteal-phase GnRH agonist as reference

    FDA-approved indication is "the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation" — on this condition the registrational endpoint is the outcome itself: a premature LH surge before hCG (LH rise >= 10 mIU/mL with progesterone > 2 ng/mL or a significant oestradiol decline) occurred in under 1% of the 463 subjects. The same trial graded as a process measure on the assisted-reproduction page is direct evidence here.

    Source DailyMed — the FDA label 1 primary source read for this row

Every compound checked earned a row

Nothing was checked against premature lh surge and set aside. That is unusual — most conditions here have a list at the bottom of this page.

What this page does not say

It reports what was measured, in whom, and how directly. It does not say what to take or at what dose, and a row here is a record of a study rather than a reason to use anything. Every rung links to the rubric that assigned it.